Orphan Drugs: Top 10 Chemotherapy And Targeted Cancer Products By US Sales
In the August 2014 issue of Medical Marketing & Media (MM&M), the publication reviews advances in cancer treatment using immunotherapy and discusses the future of these new agents in the fight against cancer. Per the article, recent research indicates that:
“… immunotherapy – once perceived as an interesting treatment for a handful of cancer tumors – may be effective against a much wider range of cancers. Moreover, the research is being greeted by an eager FDA, which a few years back created a fast-track approval program – known as Breakthrough Therapy Designation – to bring life-threatening drugs to market much more quickly.”
Of the 5 FDA Breakthrough Therapy Designations (BTDs) receiving approval (as of 07/23/14), 4 or 80% are for an oncology indication. Of the 49 FDA BTDs (as of 07/21/14), approximately 47% are for an oncology indication.
The following chart shows the top 10 chemotherapy and targeted cancer products (by US Sales – 2013), that have FDA Orphan Drug Designations (ODDs) :
Orphan Drugs: Top 10 Chemotherapy/Targeted Cancer Products By US Sales (2013)
|Rank||Product||Manufacturer||US Sales ($ Millions *||# of FDA Orphan Drug Designations(ODDs) **|
* Sales, IMS Health (per MM&M article chart)
** # of FDA ODDs from FDA’s Orphan Drug Product Designation Database (provided by the Orphan Druganaut Blog).
For the other rankings, please reference the article.
Copyright © 2012-2014, Orphan Druganaut Blog. All rights reserved.